Proof-of-Concept Study of Pipamperone Added to Stable Treatment With Risperidone or Paliperidone in Chronic Schizophrenia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by PharmaNeuroBoost N.V..
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
PharmaNeuroBoost N.V.
ClinicalTrials.gov Identifier:
NCT01450514
First received: October 7, 2011
Last updated: June 6, 2012
Last verified: June 2012

October 7, 2011
June 6, 2012
March 2012
November 2012   (final data collection date for primary outcome measure)
Change from baseline in functional MRI tests [ Time Frame: 1 day, 2 weeks and 6 weeks after study treatment start ] [ Designated as safety issue: No ]
MRI = Magnetic Resonance Imaging Functional tests performed during MRI include the N-Back Test and the Monetary Incentive Delay (MID) Task Test
Change from baseline in individual positive PANSS score items [ Time Frame: 2 weeks and 6 weeks after study treatment start ] [ Designated as safety issue: No ]
PANSS = Positive and Negative Syndrome Scale
Complete list of historical versions of study NCT01450514 on ClinicalTrials.gov Archive Site
  • Change from baseline in residual PANSS item(s) [ Time Frame: 2 weeks and 6 weeks after study treatment start ] [ Designated as safety issue: No ]
    PANSS = Positive and Negative Syndrome Scale
  • Change from baseline in SWN score and subitem scores [ Time Frame: 2 weeks and 6 weeks after study treatment start ] [ Designated as safety issue: No ]
    SWN = Subjective Well-being under Neuroleptics questionnaire
  • Change from baseline in IMI-SR score and subitem scores [ Time Frame: 2 weeks and 6 weeks after study treatment start ] [ Designated as safety issue: No ]
    IMI-SR = Intrinsic Motivation Inventory for Schizophrenia Research (questionnaire)
  • CGI-I score [ Time Frame: 2 weeks and 6 weeks after study treatment start ] [ Designated as safety issue: No ]
    CGI-I = Clinical Global Impression if Improvement
  • Change from baseline in BARS total and subitem scores [ Time Frame: 6 weeks after study treatment start ] [ Designated as safety issue: Yes ]
    BARS = Barnes Akathisia Rating Scale
  • Change from baseline in BACS score and subitem scores [ Time Frame: 1 day, 2 weeks and 6 weeks after study treatment start ] [ Designated as safety issue: No ]
    BACS = Brief Assessment of Cognition Scale
Brief Assessment of Cognition in Schizophrenia (BACS) [ Time Frame: 2 and 6 weeks after study treatment start ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Proof-of-Concept Study of Pipamperone Added to Stable Treatment With Risperidone or Paliperidone in Chronic Schizophrenia
Proof-of-Concept Study of Pipamperone 15mg Added to Stable Risperidone or Paliperidone Treatment in Chronic Schizophrenic and Schizoaffective Patients With Residual Symptoms: a Phase I/IIa, Randomized, Double-blind, Placebo-controlled Trial of 7 Weeks

This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or paliperidone (PAL) on functional MRI tests and clinical outcome of chronic schizophrenic patients with residual, so-called 'positive' symptoms, as well as on cognition, motivation, subjective well-being of patients, negative symptoms, general psychopathological symptoms and safety/tolerability. This exploratory study of 7 weeks will be performed in 40 to 60 patients in up to 10 centers in Belgium. In a subset of patients, the 6-week treatment phase will be preceded by a single-dose cross-over phase with 1 week of wash-out. While the objective of the study, due to its exploratory design, is to assess any effect of the study medication on MRI or clinical outcome, the study medication is expected to improve the residual (remaining) positive symptom(s) of patients. In addition, genetic and pharmacokinetic testing may be performed to learn more about the disorder and its treatment.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Chronic Schizophrenia
  • Schizoaffective Disorder
  • Drug: Pipamperone
    15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
    Other Name: Risperdal, Invega and Xeplion
  • Drug: sugar pill
    15 mg matching placebo once daily per os on top of continued stable treatment with RIS or PAL
  • Placebo Comparator: sugar pil
    Intervention: Drug: sugar pill
  • Experimental: Pipamperone
    Intervention: Drug: Pipamperone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
Not Provided
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent.
  • Patient understands the investigational nature of the trial and is willing and able to comply with the trial requirements.
  • Patient is male or female, aged 18-65 years.
  • Patients has Schizophrenia or Schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-R criteria. Diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • Patient is being treated during at least 12 weeks with a stable dosage of either risperidone depot of 12.5-50mg IM every 2 weeks, paliperidone depot of 25-100mg IM every 4 weeks, risperidone oral administration of 2-6 mg/d, or paliperidone oral administration of 4-12 mg/d
  • Patient has a CGI-S score of 3 (mildly ill) or more at baseline.
  • Patient has a score of 4 or more on at least 1 item of the positive PANSS subscale (residual symptoms).

Exclusion Criteria:

  • Acute exacerbation of schizophrenic or schizoaffective disorder during the past 12 weeks.
  • Documented debility or an IQ below 85.
  • Comorbid axis 1 conditions (including anxiety disorders, eating disorders, impulse control disorders) requiring drug treatment over the previous 12 weeks.
  • Patient has taken, in the past 6 weeks prior to randomization, any newly initiated psychoactive drug.
  • Patient was withdrawn from psychoactive drug treatment in the past week or within a period shorter than 5x the elimination half-life of any psychoactive drug. Withdrawal of any prior antipsychotic treatment should not have occurred within 6 weeks prior to baseline.
  • Concomitant treatment with any additional antipsychotic drug at a therapeutic dosage, diuretics, QT prolongation drugs, or dopamine agonists.
  • Formal cognitive psychotherapy initiated during study treatment or within 6 weeks prior to randomization.
  • Patient has any other medical or psychiatric condition, which in the opinion of the investigator, can jeopardize or would compromise the patient's ability to participate in this trial or that would interfere with trial assessments.
  • Patient with a DSM-IV alcohol or substance dependence diagnosis (within the last 6 months), an alcohol or substance abuse diagnosis (within the last month) or having a positive standard screen for alcohol or drugs (including benzodiazepines and opioids).
  • 'Any concomitant psychoactive treatment (including psychotherapy)' or 'Patient received, in the 6 weeks prior to randomization any newly prescribed psychoactive drug'.
  • Patient is pregnant, nursing, or is a woman of child-bearing potential who is not surgically sterile, 2 years postmenopausal, or who does not consistently use 2 combined effective methods of contraception (including at least 1 barrier method), unless sexually abstinent.
Both
18 Years to 65 Years
No
Contact: Philippe Lemmens, PhD +32 11 48 07 54 philippe.lemmens@pharmaneuroboost.com
Belgium
 
NCT01450514
PNB02-C201, 2011-004494-81
No
PharmaNeuroBoost N.V.
PharmaNeuroBoost N.V.
Not Provided
Principal Investigator: Marc De Hert, M.D., PhD University Psychiatric Institute Sint-Jozef Leuvensesteenweg 517 B-3070 Kortenberg, Belgium
PharmaNeuroBoost N.V.
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP